Back to Startup Insights
Braveheart Bio
Late clinical-stage company developing BHB-1893, a selective small-molecule cardiac myosin inhibitor, to transform care of hypertrophic cardiomyopathy and related conditions.
Headquarters
San Francisco, USA
Year Founded
2024
Founders
Travis Murdoch (CEO), David Malek
Country
United States
Financial Information
Funding Stage
Series A
Recent Funding
$185M
Funding By
Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, Frazier Life Sciences
Core Technology
Selective cardiac myosin inhibitor (BHB-1893)
Product Type
Drug
Pipeline Stage (Very Important)
Late-stage clinical
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: Late-stage HCM (BHB-1893)
- Patents / IP Status: Filed
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
None disclosed
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Late-stage HCM myosin inhibitor backed by a top-tier cardiovascular syndicate